This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at https://www.rt.com/news/537246-india-covaxin-vaccine-covid19-kids/

The article has changed 2 times. There is an RSS feed of changes available.

Version 0 Version 1
Indian drugs regulator backs home-grown Bharat Biotech's Covid-19 for kids aged 2 and above Indian drugs regulator backs home-grown Bharat Biotech's Covid-19 for kids aged 2 and above
(7 days later)
The Indian drugs regulator has recommended the use of Bharat Biotech's Covid-19 shot for emergency use in children aged between two and 18 years old. It will become the first shot to be used on under-12s in India.The Indian drugs regulator has recommended the use of Bharat Biotech's Covid-19 shot for emergency use in children aged between two and 18 years old. It will become the first shot to be used on under-12s in India.
On Tuesday, the Central Drugs Standard Control Organisation and Subject Expert Committee said that the Covaxin shot, produced by Indian firm Bharat Biotech could be administered to children between the ages of two and 18.On Tuesday, the Central Drugs Standard Control Organisation and Subject Expert Committee said that the Covaxin shot, produced by Indian firm Bharat Biotech could be administered to children between the ages of two and 18.
Clinical-trial data from Bharat Biotech "has been thoroughly reviewed by the Central Drugs Standard Control Organisation and Subject Expert Committee and [they] have provided their positive recommendations," the vaccine maker told Reuters in a statement. Clinical-trial data from Bharat Biotech "has been thoroughly reviewed by the Central Drugs Standard Control Organisation and Subject Expert Committee and [they] have provided their positive recommendations," the vaccine maker told Reuters in a statement. 
The firm is yet to publicly share its data from trials involving children. The vaccine is now the second to be recommended for use on recipients under the age of 18, after Zydus Cadila's DNA vaccine. Although the Zydus shot is only authorized for use in those above the age of 12.The firm is yet to publicly share its data from trials involving children. The vaccine is now the second to be recommended for use on recipients under the age of 18, after Zydus Cadila's DNA vaccine. Although the Zydus shot is only authorized for use in those above the age of 12.
Covaxin is similar to China's CoronaVac (the Chinese vaccine developed by Sinovac), using an inactivated coronavirus paired with the adjuvant Alhydroxiquim-II to boost immune response. The shot is taken as part of a two-dose regimen, recommended to be taken 28 days apart. Covaxin is similar to China's CoronaVac (the Chinese vaccine developed by Sinovac), using an inactivated coronavirus paired with the adjuvant Alhydroxiquim-II to boost immune response. The shot is taken as part of a two-dose regimen, recommended to be taken 28 days apart. 
Some 110 million doses of the vaccine have been administered to date. The firm hopes to receive emergency-use listing from the World Health Organization later this month.Some 110 million doses of the vaccine have been administered to date. The firm hopes to receive emergency-use listing from the World Health Organization later this month.
India has now administered 960 million vaccines in the fight against Covid-19, with the British-developed AstraZeneca vaccine at the heart of the effort. The inoculation campaign is increasingly focusing on children, with many adults already vaccinated.India has now administered 960 million vaccines in the fight against Covid-19, with the British-developed AstraZeneca vaccine at the heart of the effort. The inoculation campaign is increasingly focusing on children, with many adults already vaccinated.
If you like this story, share it with a friend!If you like this story, share it with a friend!
Dear readers and commenters,
We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system.
Sorry for the inconvenience, and looking forward to your future comments,
RT Team.